EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY-NC 3.0

Characteristics and Outcomes of People With COPD Who Experience Exacerbations While on Inhaled Triple Therapy: Results of the SIRIUS I Cohort Study in the US (2015–2019)

Clementine Nordon, Donna Carstens, Malin Fagerås, Hana Müllerová iD, Phani S Veeranki, João André Alves, Hayley D Germack, Timothy L Barnes iD, Meredith C McCormack iD

International Journal of Chronic Obstructive Pulmonary Disease · 2025-06 · Volume 20 · 1851-1864

DOI: 10.2147/copd.s513573 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025-06. Verfasst von Clementine Nordon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Bronchodilator Agents, Adrenal Cortex Hormones, Lung. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveBronchodilator AgentsAdrenal Cortex HormonesLungHumansFemaleMaleRetrospective StudiesMiddle AgedAdministration, InhalationAgedUnited StatesDisease ProgressionDrug Therapy, CombinationTreatment OutcomeTime FactorsRisk FactorsSmoking

Stichwörter der Autor:innen

COPDburden of illnessexacerbationhealthcare resource utilizationinhaled triple therapymortality

Substanzen

Bronchodilator AgentsAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Respiratory Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • US Medical Evidence, Biopharmaceuticals, AstraZeneca, Wilmington, DE, USA.
  • Global Medical, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
  • Value & Evidence Solutions, Optum Life Sciences, Eden Prairie, MN, USA.
  • School of Medicine, Johns Hopkins Medicine, Baltimore, MA, USA.

ORCID-Profile: Hana Müllerová, Timothy L Barnes, Meredith C McCormack

Förderung

  • AstraZeneca

Zitieren

APA

Nordon, C., Carstens, D., Fagerås, M., Müllerová, H., Veeranki, P. S., Alves, J. A., Germack, H. D., Barnes, T. L., & McCormack, M. C. (2025). Characteristics and Outcomes of People With COPD Who Experience Exacerbations While on Inhaled Triple Therapy: Results of the SIRIUS I Cohort Study in the US (2015–2019). International Journal of Chronic Obstructive Pulmonary Disease, Volume 20, 1851-1864. https://doi.org/10.2147/copd.s513573

Vancouver

Nordon C, Carstens D, Fagerås M, Müllerová H, Veeranki PS, Alves JA, et al. Characteristics and Outcomes of People With COPD Who Experience Exacerbations While on Inhaled Triple Therapy: Results of the SIRIUS I Cohort Study in the US (2015–2019). International Journal of Chronic Obstructive Pulmonary Disease. 2025;Volume 20:1851-1864. doi:10.2147/copd.s513573

BibTeX
@article{Nordon2025,
  author = {Nordon, Clementine and Carstens, Donna and Fagerås, Malin and Müllerová, Hana and Veeranki, Phani S and Alves, João André and Germack, Hayley D and Barnes, Timothy L and McCormack, Meredith C},
  title = {Characteristics and Outcomes of People With COPD Who Experience Exacerbations While on Inhaled Triple Therapy: Results of the SIRIUS I Cohort Study in the US (2015–2019)},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  volume = {Volume 20},
  pages = {1851--1864},
  doi = {10.2147/copd.s513573}
}
Kostenlos starten →